Prognostic value of serum soluble interleukin-2 receptor level in patients with diffuse large B cell lymphoma, treated with CHOP- or RCHOP-based therapy

References

• The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993; 329: 987–994
   PubMed Web of Science ®Google Scholar
• Rubin L A, Galli F, Greene W C, Nelson D L, Jay G. The molecular basis for the generation of the human soluble interleukin 2 receptor. Cytokine 1990; 2: 330–336
   PubMedGoogle Scholar
• Wagner D K, Kiwanuka J, Edwards B K, Rubin L A, Nelson D L, Magrath I T. Soluble interleukin-2 receptor levels in patients with undifferentiated and lymphoblastic lymphomas: correlation with survival. J Clin Oncol 1987; 5: 1262–1274
   PubMed Web of Science ®Google Scholar
• Harrington D S, Patil K, Lai P K, Yasuda N N, Armitage J O, Ip S H, et al. Soluble interleukin 2 receptors in patients with malignant lymphoma. Arch Pathol Lab Med 1988; 112: 597–601
   PubMed Web of Science ®Google Scholar
• Yasuda N, Lai P K, Ip S H, Kung P C, Hinuma Y, Matsuoka M, et al. Soluble interleukin 2 receptors in sera of Japanese patients with adult T cell leukemia mark activity of disease. Blood 1988; 71: 1021–1026
   PubMed Web of Science ®Google Scholar
• Stasi R, Conforti M, Del Poeta G, Simone M D, Coppetelli U, Tribalto M, et al. Soluble factors levels in the initial staging of high-grade non-Hodgkin's lymphomas. Haematologica 1992; 77: 518–521
   PubMed Web of Science ®Google Scholar
• Kono N, Kanda Y, Yamamoto R, Chizuka A, Suguro M, Hamaki T, et al. Prognostic significance of serum soluble interleukin-2 receptor level in non-Hodgkin's lymphoma: a single center study in Japan. Leuk Lymphoma 2000; 37: 151–156
   PubMed Web of Science ®Google Scholar
• Niitsu N, Iijima K, Chizuka A. A high serum-soluble interleukin-2 receptor level is associated with a poor outcome of aggressive non-Hodgkin's lymphoma. Eur J Haematol 2001; 66: 24–30
   PubMed Web of Science ®Google Scholar
• Goto H, Tsurumi H, Takemura M, Ino-Shimomura Y, Kasahara S, Sawada M, et al. Serum-soluble interleukin-2 receptor (sIL-2R) level determines clinical outcome in patients with aggressive non-Hodgkin's lymphoma: in combination with the International Prognostic Index. J Cancer Res Clin Oncol 2005; 131: 73–79
   PubMed Web of Science ®Google Scholar
• Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 235–242
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Trumper L, Osterborg A, Pettengell R, Trneny M, Imrie K, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006; 7: 379–391
   PubMed Web of Science ®Google Scholar
• Lai C K, Chan C H, Leung J C, Lai K N. Serum concentration of soluble interleukin 2 receptors in asthma. Correlation with disease activity. Chest 1993; 103: 782–786
   PubMed Web of Science ®Google Scholar
• Rubin L A, Snow K M, Kurman C C, Nelson D L, Keystone E C. Serial levels of soluble interleukin 2 receptor in the peripheral blood of patients with rheumatoid arthritis: correlations with disease activity. J Rheumatol 1990; 17: 597–602
   PubMed Web of Science ®Google Scholar
• Uziel Y, Krafchik B R, Feldman B, Silverman E D, Rubin L A, Laxer R M. Serum levels of soluble interleukin-2 receptor. A marker of disease activity in localized scleroderma. Arthritis Rheum 1994; 37: 898–901
   PubMed Web of Science ®Google Scholar
• Hurteau J A, Woolas R P, Jacobs I J, Oram D C, Kurman C C, Rubin L A, et al. Soluble interleukin-2 receptor alpha is elevated in sera of patients with benign ovarian neoplasms and epithelial ovarian cancer. Cancer 1995; 76: 1615–1620
   PubMed Web of Science ®Google Scholar
• Yokose N, Ogata K, Ito T, An E, Tamura H, Dan K, et al. Elevated plasma soluble interleukin 2 receptor level correlates with defective natural killer and CD8 + T-cells in myelodysplastic syndromes. Leuk Res 1994; 18: 777–782
   PubMed Web of Science ®Google Scholar
• Hans C P, Weisenburger D D, Greiner T C, Gascoyne R D, Delabie J, Ott G, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004; 103: 275–282
   PubMed Web of Science ®Google Scholar
• Muris J J, Meijer C J, Vos W, van Krieken J H, Jiwa N M, Ossenkoppele G J, et al. Immunohistochemical profiling based on Bcl-2, CD10 and MUM1 expression improves risk stratification in patients with primary nodal diffuse large B cell lymphoma. J Pathol 2006; 208: 714–723
   PubMed Web of Science ®Google Scholar
• Novak A J, Grote D M, Stenson M, Ziesmer S C, Witzig T E, Habermann T M, et al. Expression of BLyS and its receptors in B-cell non-Hodgkin lymphoma: correlation with disease activity and patient outcome. Blood 2004; 104: 2247–2253
   PubMed Web of Science ®Google Scholar
• Oki Y, Georgakis G V, Migone T S, Kwak L W, Younes A. Elevated serum BLyS levels in patients with non-Hodgkin lymphoma. Leuk Lymphoma 2007; 48: 1869–1871
   PubMed Web of Science ®Google Scholar
• Aydin F, Yilmaz M, Ozdemir F, Kavgaci H, Yavuz M N, Yavuz A A. Correlation of serum IL-2, IL-6 and IL-10 levels with International Prognostic Index in patients with aggressive non-Hodgkin's lymphoma. Am J Clin Oncol 2002; 25: 570–572
   PubMed Web of Science ®Google Scholar
• Fabre-Guillevin E, Tabrizi R, Coulon V, Monnereau A, Eghbali H, Soubeyran I, et al. Aggressive non-Hodgkin's lymphoma: concomitant evaluation of interleukin-2, soluble interleukin-2 receptor, interleukin-4, interleukin-6, interleukin-10 and correlation with outcome. Leuk Lymphoma 2006; 47: 603–611
   PubMed Web of Science ®Google Scholar
• Stasi R, Zinzani L, Galieni P, Lauta V M, Damasio E, Dispensa E, et al. Detection of soluble interleukin-2 receptor and interleukin-10 in the serum of patients with aggressive non-Hodgkin's lymphoma. Identification of a subset at high risk of treatment failure. Cancer 1994; 74: 1792–1800
   PubMed Web of Science ®Google Scholar
• Vonderheid E C, Zhang Q, Lessin S R, Polansky M, Abrams J T, Bigler R D, et al. Use of serum soluble interleukin-2 receptor levels to monitor the progression of cutaneous T-cell lymphoma. J Am Acad Dermatol 1998; 38: 207–220
   PubMed Web of Science ®Google Scholar
• Marcon L, Rubin L A, Kurman C C, Fritz M E, Longo D L, Uchiyama T, et al. Elevated serum levels of soluble Tac peptide in adult T-cell leukemia: correlation with clinical status during chemotherapy. Ann Intern Med 1988; 109: 274–279
   PubMed Web of Science ®Google Scholar